Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, leading to vasodilation and reduced myocardial contractility.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Short-term treatment of hypertension when oral therapy is not feasible or desirable,Management of perioperative hypertension
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion: initial rate 5 mg/hour, titrate by 2.5 mg/hour every 15 minutes as needed up to 15 mg/hour. For acute hypertension, 5 mg/hour initial, increase by 2.5 mg/hour every 5-15 minutes to maximum 15 mg/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is 2 to 4 hours; prolonged in hepatic impairment or with continuous infusion.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Primarily hepatic via cytochrome P450 3A4, with minor contribution from 2C8 and 2D6. Metabolites are inactive.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 35% of metabolites.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
>95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Approximately 0.7 L/kg (range 0.6-0.8 L/kg). Large Vd indicates extensive tissue distribution, including central nervous system.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: approximately 35% (extensive first-pass metabolism). IV: 100%.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dose adjustment required for GFR >= 30 m L/min. For GFR < 30 m L/min, use with caution and consider starting at lower doses (e.g., 3-5 mg/hour) due to potential accumulation.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh Class A: No adjustment. Child-Pugh Class B or C: Reduce initial dose by 50% (e.g., start at 2.5 mg/hour) and titrate slowly.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Not FDA-approved for pediatric use. Limited data: intravenous infusion starting at 0.5-1 mcg/kg/min, titrate as needed; maximum 3-5 mcg/kg/min. Alternatively, for hypertensive emergencies: 0.5-3 mcg/kg/min continuous infusion.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Start at lower end of dosing range (3-5 mg/hour intravenous) and titrate slowly due to increased sensitivity and potential for hypotension. Monitor closely.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA black box warning.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May cause hypotension, especially with rapid dose escalation or in patients with compromised cardiac function,Use with caution in patients with heart failure, as negative inotropic effects may worsen symptoms,Avoid in patients with severe aortic stenosis due to risk of reduced coronary perfusion
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to nicardipine or any component of the formulation,Advanced aortic stenosis (absolute)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing nicardipine levels and risk of adverse effects.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity and fetotoxicity at doses 4-10 times the maximum recommended human dose. Second and third trimesters: May cause maternal hypotension and fetal hypoxia; avoid use unless potential benefit outweighs risk. No adequate well-controlled studies in pregnant women.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Unknown if excreted in human milk; M/P ratio not established. Use with caution; consider risk of infant exposure and maternal need. No data on effects on milk production.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustments; data limited. Start at low end of dosing range and titrate to clinical response. No specific dose recommendations; use lowest effective dose and monitor closely.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Nicardipine is a dihydropyridine calcium channel blocker used for rapid blood pressure reduction in hypertensive emergencies. Administer as a continuous IV infusion, titrating by 0.5-1 mg/hour every 15 minutes; maximum dose 15 mg/hour. Monitor for reflex tachycardia, hypotension, and peripheral edema. Compatible with 0.86% sodium chloride; do not mix with other medications in the same IV line. Use with caution in patients with heart failure, as negative inotropic effects may occur.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is given intravenously to quickly lower your blood pressure.,You will be monitored closely for changes in heart rate and blood pressure.,Report any chest pain, shortness of breath, or swelling in your legs or ankles.,Avoid grapefruit and grapefruit juice while on this medication due to increased risk of side effects.,Do not stop the medication abruptly without consulting your healthcare provider.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Ximelagatran, a prodrug of the direct thrombin inhibitor melagatran, is primarily metabolized by CYP450 enzymes, particularly CYP2C9 and to a lesser extent CYP3A4. Nicardipine, a dihydropyridine calcium channel blocker, is extensively metabolized by CYP3A4. Coadministration of ximelagatran with nicardipine may result in inhibition of CYP3A4-mediated metabolism of nicardipine, leading to increased nicardipine plasma concentrations, enhanced hypotensive effects, and potentially elevated risk of adverse events such as edema, headache, and dizziness."
"Cinnarizine, a piperazine derivative with antihistaminic and calcium channel-blocking properties, inhibits cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of nicardipine, a dihydropyridine calcium channel blocker. This inhibition leads to reduced clearance and elevated plasma concentrations of nicardipine, potentially resulting in enhanced vasodilation, hypotension, reflex tachycardia, and increased risk of adverse effects such as peripheral edema, dizziness, and headache. Clinically, patients may experience exaggerated hypotensive responses and cardiovascular instability."
"Etoricoxib, a selective COX-2 inhibitor, can inhibit the metabolism of nicardipine, a dihydropyridine calcium channel blocker, via competitive inhibition of CYP3A4. This results in elevated plasma concentrations of nicardipine, potentially leading to enhanced hypotensive effects and an increased risk of adverse events such as dizziness, headache, peripheral edema, and reflex tachycardia. Clinically, this interaction may necessitate dose adjustment and careful monitoring of blood pressure and heart rate."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, leading to vasodilation and reduced myocardial contractility.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE is: Intravenous infusion: initial rate 5 mg/hour, titrate by 2.5 mg/hour every 15 minutes as needed up to 15 mg/hour. For acute hypertension, 5 mg/hour initial, increase by 2.5 mg/hour every 5-15 minutes to maximum 15 mg/hour.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity and fetotoxicity at doses 4-10 times the maximum recommended human dose. Second and th. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.